MAPT and Alzheimer disease: An increasingly recognized global health problem, AD is a chronic disorder that causes amyloid beta plaques and neurofibrillary tangles of hyperphosphorylated tau to form.1,2 There is growing interest in identifying early screening biomarkers for diseases such as AD, where cognitive impairment tends to occur later in life than actual disease progression.3